Functional dyspepsia
Conditions
Interventions
Administration of anti-anxiety drug )Tandospirone Citrate) 30mg/day for one month
placebo
Sponsors
Japanese Sciety for treatment of Functional dyspepsia
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: FD patients who meet Rome II criteria 1. patients who had at least one symptom described below in one week preceding the study pain, discomfort of epigastrium, bloating, abdominal fullness, early satiety, nausea or vomiting, appetite loss, belching. 2. patients who had no organic lesions that were confirmed by upper GI endoscopy within 6 months. 3. patients who are older than 20 years at entry. 4. out patients. 5. patients who understand the study contents and give informed consents by themselves
Exclusion criteria
Exclusion criteria: 1. patients who have obvious organic lesions such as malignancy, or peptic ulcers. 2. patients who have obvious causes for the symptoms such as overeating. 3. patients whose main symptom is heartburn. 4. patients who are or ore suspected IBS. 5. patients who have past history of surgery for upper GI diseases. 6. patients who have pathological anxiety, depression or obvious mental diseases. 7. patients with severe liver and renal diseases. 8. patients who took medicines described below within one week before the first day of the study; prokinetics, acid -inhibitory drugs (H2RA, PPI), PG drugs NSAIDs. 9. patients who took anti-anxiety drug or tranquilizer within 4 weeks before beginning of the study. 10. patients who are pregnancy, in breast-feeding or who wish pregnancy during the study period. 11. patients who are regarded in-eligible by the doctor who participates in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptom resolution (improvement) | — |
Secondary
| Measure | Time frame |
|---|---|
| imprvement of quality of eibe | — |
Countries
Japan
Outcome results
None listed